Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Open accessThe DOI matches its Crossref record; 105 of the 124 references it cites were found in a registry or an index.
Abstract
Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I (Topo I). The formation of a cleavable drug-Topo I-DNA complex results in lethal double-strand DNA breakage and cell death. However, de novo or acquired clinical resistance to camptothecins is common. Studies of the camptothecin analog irinotecan suggest the following general mechanisms of resistance: (i) variable levels of the enzymes involved in the conversion of irinotecan; (ii) reduced cellular accumulation from active drug efflux; (iii) reduced levels of Topo I expression; (iv) alterations in the structure of Topo I from different mutations; (v) alterations in the cellular response to camptothecin-Topo I-DNA complex formation, which involves proteasome degradation of Topo I and/or enhanced DNA repair; and (vi) activation of the transcription factor nuclear factor kappa B by DNA damage and subsequent suppression of apoptosis. Multiple approaches using pharmacological and biological modulation to circumvent the above mechanisms of resistance have been incorporated into ongoing clinical trials and are expected to enhance the antitumor activity of irinotecan and reduce its systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Carboxylesterase 2 (CES2) is the critical enzyme for the activation of irinotecan, which can catalyze the conversion of irinotecan to the more active form of SN-38 (a topoisomerase inhibitor) [88].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
In the citing paper
“In addition, the amount of TOP-1 bound to DNA is reduced, which may also lead to CRC resistance to irinotecan [88,131].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“Initial approval in the United States was as a second-line treatment for metastatic colorectal cancer, after failure of 5-fluorouracil (5-FU) and leucovorin [2], and more recently it has been approved for use in combination with 5-FU/leucovorin as a first-line treatment for this disease [3, 4].”
BackgroundAn Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Research works printed but not linked: 8
- Ilson D, Enzinger P, Saltz L et al. Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 18: 259a (Abstr).
- Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology 1998; 12: 72-78.
- Prados M, Kuhn J, Yung W et al. A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium (NABTC) study. Proc Am Soc Clin Oncol 2001; 19: 162 (Abstr 627).
- Kameyama M, Shoichi I, Ohtsuka K et al. Activation and detoxifica- tion of CPT-11 by human lung cancer cells. Proc Am Soc Clin Oncol 2000; 19: 505a (Abstr 1975).
- Villalona-Calero MA, Kuhn JG, Drengler R et al. Pharmaco- logically-based phase I study of mitomycin C (MMC) as a modulator of irinotecan (CPT-11) antitumor activity. Proc Am Soc Clin Oncol 2001; 20: 101a (Abstr 400).
- Kolesar J, Miller J, Duan W, Villalona-Calero M. TI induction in PBMC by mitomycin-C predicts irinotecan response. Proc Am Soc Clin Oncol 2002; 21: 115 (Abstr 456).
- Ratain, 1999, A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB), Proc Am Soc Clin Oncol, 18, 202a
- Takeda, 2001, Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients, Int J Cancer, 92, 269, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3 · DOI · Paper page
Cited by
Items 201–300 of 419
Chemotherapy for the treatment of intracranial glioma in dogs
José‐López, R. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1273122 · Cited by 21
Addition of Propolis to Irinotecan Therapy Prolongs Survival in Ehrlich Ascites Tumor-Bearing Mice
Lisičić, D., Benković, V., Đikić, D., Blažević, S. A., Mihaljević, J., Oršolić, N., & Knežević, A. H. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1535 · Cited by 18
Arakawa, Y., Saito, S., Yamada, H., & Aiba, K. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0384-0 · Cited by 18
Wissing, M. D., Mendonca, J., Kim, E., Kim, E., Shim, J. S., Kaelber, N. S., Kant, H., Hammers, H. J., Commes, T., van Diest, P. J., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23759 · Cited by 17
Romano, E., Netti, P. A., & Torino, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189896 · Cited by 17
Abdulla, M., Traiki, T. A. B., Vaali‐Mohammed, M., El‐Wetidy, M. S., Alhassan, N. S., Al‐Khayal, K., Zubaidi, A. M., Al-Obeed, O. A., & Ahmad, R. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5312 · Cited by 18
Wu, Z., Li, Q., Zhu, K., Zheng, S., Hu, H., Hou, M., Li, Q., Chen, S., Xu, Y., Zhao, B., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303626 · Cited by 23
Self-citationSimvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1
Alqudah, M. A. Y., Mansour, H. T., & Mhaidat, N. M. (2017) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.12.012 · Cited by 17
Han, J., Lee, G. K., Yoo, S. Y., Yoon, S. J., Cho, E. Y., Kim, H. T., & Lee, J. S. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.46 · Cited by 17
Solubility‐Improved 10‐O‐Substituted SN‐38 Derivatives with Antitumor Activity
Doi, H., Kida, T., Nishino, K., Nakatsuji, M., Sakamoto, S., Shimizu, S., Teraoka, Y., Tamura, Y., Kataoka, Y., & Inui, T. (2017) · ChemMedChem · doi:10.1002/cmdc.201700454 · Cited by 17
Yashiro, M., Qiu, H., Hasegawa, T., Zhang, X., Matsuzaki, T., & Hirakawa, K. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.397 · Cited by 17
Cha, Y., Kim, S. Y., Yeo, H. Y., Baek, J. Y., Choi, M. K., Jung, K. H., Dong, S. M., & Chang, H. J. (2018) · Neoplasia · doi:10.1016/j.neo.2018.11.010 · Cited by 16
Khader, E., Ismail, W., Mhaidat, N. M., & Alqudah, M. A. Y. (2021) · PubMed Central · Cited by 23
Lin, H.-J., Liang, T., Chang, Y.-Y., Liu, D.-Z., Fan, J.-Y., Roffler, S. R., & Lin, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061202 · Cited by 16
Quantification and calibration of images in fluorescence microscopy
Baskin, D. S., Widmayer, M. A., & Sharpe, M. A. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.05.029 · Cited by 18
The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells
Babaei, A., Soleimanjahi, H., Soleimani, M., & Arefian, E. (2020) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-020-00361-w · Cited by 18
Lustberg, M. B., Bekaii‐Saab, T., Young, D., Otterson, G. A., Burak, W. E., Abbas, A., McCracken-Bussa, B., Lustberg, M. E., & Villalona-Calero, M. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d7776d · Cited by 16
Self-citationA cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines
Morandi, E., Zingaretti, C., Chiozzotto, D., Severini, C., Semeria, A., Horn, W., Vaccari, M., Serra, R., Silingardi, P., & Colacci, A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.017 · Cited by 19
Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100
Zhang, M., Wen, F., Zhu, L.-Z., Liu, X.-F., Li, L., Peng, L., Kai, G., Liu, Y., Zhang, Z., & Xu, C. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121105 · Cited by 15
Abdelnabi, D., Lastakchi, S., Watts, C., Atkins, H., Hingtgen, S., Valdivia, A., & McConville, C. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01524-x · Cited by 17
Vrdoljak, A. L., Fuchs, N., Mikolić, A., Žunec, S., Karačonji, I. B., Jurič, A., Prester, L., Micek, V., Neuberg, M., Čanović, S., et al. (2018) · Molecules · doi:10.3390/molecules23061332 · Cited by 15
Paule, B., Castagné, V., Picard, V., Saffroy, R., Adam, R. A., Guettier, C., Farinotti, R., & Bonhomme‐Faivre, L. (2009) · Medical Oncology · doi:10.1007/s12032-009-9336-3 · Cited by 14
Calvet, L., Santos, A., Valent, A., Terrier‐Lacombe, M., Opolon, P., Merlin, J., Aubert, G., Morizet, J., Schellens, J. H. M., Bénard, J., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602079 · Cited by 16
Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer
Yoon, S., Lee, B., & Kim, K. P. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155120 · Cited by 16
Chu, C., Abbara, C., Tandia, M., Polrot, M., Gonin, P., Farinotti, R., & Bonhomme‐Faivre, L. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12071 · Cited by 14
Rühle, P. F., Goerig, N. L., Wunderlich, R., Fietkau, R., Gaipl, U. S., Strnad, A. R., & Frey, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00296 · Cited by 14
Skarkova, V., Králová, V., Krbal, L., Matoušková, P., Soukup, J., & Rudolf, E. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.05.032 · Cited by 11
Kolesar, J. (2010) · Molecular Medicine Reports · doi:10.3892/mmr.2010.366 · Cited by 12
Poorebrahim, M., Sadeghi, S., Ghanbarian, M., Kalhor, H., Mehrtash, A., & Teimoori‐Toolabi, L. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03975-3 · Cited by 12
The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study
Garrett, A.-M., Lastakchi, S., & McConville, C. (2020) · Genes · doi:10.3390/genes11020173 · Cited by 18
Predictive and Prognostic Markers in Colorectal Cancer
Turkington, R. C., Coyle, V. M., Johnston, P. G., & Eatock, M. M. (2007) · Personalized Medicine · doi:10.2217/17410541.4.3.295 · Cited by 12
Xing, J., Liu, C.-Y., Zhang, W., Chai, R., Li, Y., Zhang, Z., Zhao, Z., Sun, J., He, Z., Jiang, X., et al. (2025) · Science China Chemistry · doi:10.1007/s11426-025-2760-2 · Cited by 11
KONG, F., WU, K., PANG, L., Huang, Y.-L., LI, L., XU, J., LI, F., QING, Y., WANG, Z., HUANG, X., et al. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.027301 · Cited by 11
Manzanares-Guevara, L. A., Gasperin-Bulbarela, J., Cabanillas-Bernal, O., Renteria-Maciel, M., Licea‐Claveríe, A., Méndez, E. R., & Licea-Navarro, A. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0294874 · Cited by 11
Microbiota Modulates the Immunomodulatory Effects of Filifolinone on Atlantic Salmon
Parra, M., Espinoza, D., Valdés, N., Vargas, R. A., González, A., Modak, B., & Tello, M. (2020) · Microorganisms · doi:10.3390/microorganisms8091320 · Cited by 12
van der Merwe, L., Svitina, H. M., Willers, C., Wrzesinski, K., & Gouws, C. (2022) · Biotechnology Progress · doi:10.1002/btpr.3253 · Cited by 11
Yang, X., Zhang, J., Xiong, M., Yang, Y., Pan, Y., Li, N., Shi, F., Zhu, Y., Guo, K., & Jin, Y. (2023) · Toxicology Letters · doi:10.1016/j.toxlet.2023.06.014 · Cited by 11
Plant-based natural products in cancer therapeutics
Mahato, R., Behera, D. K., Patra, B., Das, S., Lakra, K., Pradhan, S. N., Abbas, S. J., & Ali, S. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2315474 · Cited by 13
Huang, Y., Yuan, J., Ding, H., Song, Y.-S., Qian, G., Wang, J., Ji, M., & Zhang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.091 · Cited by 11
Clegg, J. R., Sun, J. A., Gu, J., Venkataraman, A. K., & Peppas, N. A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.045 · Cited by 11
Kumar, S., Singh, S. K., Srivastava, P., Suresh, S., Rana, B., & Rana, A. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.003 · Cited by 10
van Niekerk, A., Wrzesinski, K., Steyn, D., & Gouws, C. (2023) · Cells · doi:10.3390/cells12151980 · Cited by 12
Wright, C., Gordon, E. R., & Cooper, S. J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11645-0 · Cited by 12
Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients
Villalona-Calero, M. A., Schaaf, L. J., Phillips, G. S., Otterson, G. A., Panico, K., Duan, W., Kleiber, B., Shah, M. H., Young, D. C., Wu, W.-H., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0249-y · Cited by 10
Self-citationThe combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells
Takigawa, N., Takeyama, M., Shibayama, T., Tada, A., Kawata, N., Okada, C., Aoe, K., Kozuki, T., Hotta, K., Tabata, M., et al. (2006) · Oncology Reports · doi:10.3892/or.15.4.837 · Cited by 10
Frye, C. C., Tennant, L., Yeager, A., Azimzadeh, P., Bhardwaj, P., Xu, Y., Liu, J., Othoum, G., Maher, C. A., Chernock, R. D., et al. (2024) · Surgery · doi:10.1016/j.surg.2024.05.006 · Cited by 10
Self-citationMoreira, H., Szyjka, A., Bęben, D., Siwiela, O., Radajewska, A., Stankiewicz, N., Grzesiak, M., Wiatrak, B., Emhemmed, F., Muller, C. D., et al. (2024) · Cancers · doi:10.3390/cancers16193279 · Cited by 9
Understanding microRNA-Mediated Chemoresistance in Colorectal Cancer Treatment
Valenzuela, G., Contreras, H. R., Marcelain, K., Burotto, M., & González‐Montero, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031168 · Cited by 11
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance
suri, C., Pande, B., Sahithi, L. S., Swarnkar, S., Khelkar, T., & Verma, H. K. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.164 · Cited by 14
Antitumor activity of irinotecan with ellagic acid in C6 glioma cells
Çetin, A., Biltekin, B., & Özevren, H. (2022) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20220130 · Cited by 9
Wei, C., Zhou, L., Yang, Y., Niu, L., & Yan, H. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14145 · Cited by 12
Xiao, Y., Yang, J., Deng, Y. P., Zhang, L., Xu, Q., & Li, H. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106768 · Cited by 10
Scianò, F., Terrana, F., Pecoraro, C., Parrino, B., Cascioferro, S., Diana, P., Giovannetti, E., & Carbone, D. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0234 · Cited by 11
Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells
Kontek, R., Matlawska‐Wasowska, K., Kalinowska‐Lis, U., & Marciniak, B. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.07.005 · Cited by 9
Recent Data with Anti—Epidermal Growth Factor Receptor Antibodies and Irinotecan in Colon Cancer
Chua, Y. J., & Cunningham, D. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.s.011 · Cited by 9
Xu, Y., Kolesar, J., Schaaf, L. J., Drengler, R. L., Duan, W., Otterson, G. A., Shapiro, C. L., Kuhn, J. G., & Villalona-Calero, M. A. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0826-3 · Cited by 9
Self-citationDeepak, P., & Ehrenpreis, E. D. (2011) · Disease-a-Month · doi:10.1016/j.disamonth.2011.05.005 · Cited by 11
Stable disease in advanced colorectal cancer: therapeutic implications.
Pasetto, L. M., D'Andrea, M. R., Jirillo, A., Rossi, E. G., & Monfardini, S. (2006) · PubMed · Cited by 9
Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
Nemes, A. (2010) · doi:10.1002/9783527630035.ch8 · Cited by 9
Urbanowicz, M., Urbanowicz, M., Bobrowska, K., Sadowska, K., Paziewska−Nowak, A., & Pijanowska, D. G. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134701 · Cited by 8
Gurbuz, H. N., Yılmaz, K., Ipekcı, H. H., Uzunoğlu, A., & Maltaş, E. (2023) · Materials Science and Engineering B · doi:10.1016/j.mseb.2023.116909 · Cited by 10
Optimizing structural design in SN38 delivery: More assembly stability and activation efficiency
Li, Y., Li, L., Hao, Y., Zhang, J., Liu, C., Zhao, E., Shi, X., Pu, X., Sun, J., He, Z., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102450 · Cited by 8
Hagiwara, T., Sugimoto, K., Momose, H., Irie, T., Honjo, K., Okazawa, Y., Kawai, M., Kawano, S., Munakata, S., Takahashi, M., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.15528 · Cited by 8
Wander, P., Arentsen-Peters, S. T. C. J. M., Vrenken, K. S., Pinhanços, S. S., Koopmans, B., Dolman, M. E. M., Jones, L., Castro, P. G., Schneider, P., Kerstjens, M. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030638 · Cited by 9
Hebbar, M., Fiore, F. D., Conroy, T., Giraud, C., Gasnault, L., Fournier, C., Péreira, R., Bouché, O., Fournier, P., Deligny, N., et al. (2007) · Oncology · doi:10.1159/000127385 · Cited by 9
di Nunzio, M. R., Douhal, Y., Organero, J. Á., & Douhal, A. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp01134f · Cited by 8
McConville, C., Lastakchi, S., Amri, A. A., Ngoga, D., Fayeye, O., & Cruickshank, G. S. (2024) · Cancers · doi:10.3390/cancers16173008 · Cited by 9
Microfluidic device for high-throughput cancer drug screenings
Chen, P., Wang, L., Chang, C., Chien, Y.-S., Su, Y., Wang, C. L., Wu, K., Chin, H.-J. G., & Chen, C.-F. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.169510 · Cited by 8
Kroupová, J., Hanuš, J., & Štĕpánek, F. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.10.003 · Cited by 8
Intestinal Flora in Chemotherapy Resistance of Biliary Pancreatic Cancer
Bai, L., Yan, X.-D., Lv, J., Qi, P., Song, X., & Zhang, L. (2023) · Biology · doi:10.3390/biology12081151 · Cited by 8
Elhamipour, M., Soleimanjahi, H., Abdoli, A., Sharifi, N., Karimi, H., jahi, S. S., & Kvistad, R. (2024) · Intervirology · doi:10.1159/000542356 · Cited by 7
Management of Two Cases of Recurrent Anal Carcinoma
Klimant, E., & Markman, M. M. (2013) · Case Reports in Oncology · doi:10.1159/000355004 · Cited by 7
5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner
Higby, K. J., Bischak, M. M., Campbell, C. A., Anderson, R. G., Broskin, S. A., Foltz, L., Koper, J. A., Nickle, A. C., & Resendes, K. K. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1338-y · Cited by 11
MicroRNAs as a Tool to Aid Stratification of Colorectal Cancer Patients and to Guide Therapy
Goblirsch, M. J., Richtig, G., Slabý, O., Berindan‐Neagoe, I., Gerger, A., & Pichler, M. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0004 · Cited by 8
Drug Resistance Mechanisms on Colorectal Cancer
Kurter, H., YEŞİL, J., Daşkın, E., Calibasi‐Kocal, G., Ellıdokuz, H., & Başbınar, Y. (2021) · Journal of Basic and Clinical Health Sciences · doi:10.30621/jbachs.869310 · Cited by 8
Lastakchi, S., Olaloko, M. K., & McConville, C. (2022) · Cancers · doi:10.3390/cancers14112602 · Cited by 7
Morinaka, T., Sakai, N., Takayashiki, T., Kuboki, S., Takano, S., Ohira, G., Matsubara, H., & Ohtsuka, M. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5568 · Cited by 8
Choi, S. H., Hong, H. K., Cho, Y. B., Lee, W. Y., & Yoo, H. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126830 · Cited by 9
Design, synthesis and antitumor activity of a novel PEG-A6-conjugated irinotecan derivative
Huang, Y., Yuan, J., Ding, H.-F., Song, Y.-S., Qian, G., Wang, J., Ji, M., & Zhang, Y. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126847 · Cited by 7
Design and evaluation of glutathione responsive glycosylated camptothecin nanosupramolecular prodrug
Li, W., Chen, Z., Li, L., Lian, M., Peng, H., & Zhang, C. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1977424 · Cited by 8
Gladilina, Y. A., Bey, L., Hilal, A., NEBORAK, E. V., Blinova, V. G., & Zhdanov, D. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031863 · Cited by 7
Janjigian, Y. Y., Ku, G. Y., Campbell, J., Shah, M. A., Capanu, M., Kelsen, D. P., & Ilson, D. H. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318271b14f · Cited by 7
Okumura, M., Iwakiri, T., Takagi, A., Hirabara, Y., Kawano, Y., & Arimori, K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.095 · Cited by 7
Glioblastoma as a Novel Drug Repositioning Target: Updated State
Hosseinalizadeh, H., Ebrahimi, A., Tavakoli, A., & Monavari, S. H. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230202163112 · Cited by 6
Targeting the CDK7-MDK axis to suppresses irinotecan resistance in colorectal cancer
Huang, W.-L., Hsu, Y.-C., Luo, C., Chang, S., Hung, Y., Lai, C.-Y., Yang, Y.-T., Chen, Y.-Z., Wu, C., Chen, F.-M., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122914 · Cited by 9
Wang, Y., Zhang, W., Yip, H., Qu, C., Hu, H., Chen, X., Lee, T., Yang, X., Yang, B., Kumar, P., et al. (2023) · Patterns · doi:10.1016/j.patter.2023.100686 · Cited by 8
Yu, K. H., Cockrum, P. C., Surinach, A., Lamarre, N., Wang, S., & O'Reilly, E. M. (2023) · Cancer Medicine · doi:10.1002/cam4.5714 · Cited by 6
Nishikawa, M., Miyake, H., & Fujisawa, M. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0861-0 · Cited by 6
Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis
Huang, M.-Y., Pan, H., Liang, Y., Wei, H., Xu, L., Zha, Q., He, X., & Ouyang, D. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1193-2 · Cited by 6
Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review
Rossana, B., Scartozzi, M., Federica, F., Squadroni, M., Santinelli, A., Italo, B., Fabris, G., & Cascinu, S. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.03.003 · Cited by 7
Wright, M. A., Morrison, G., Lin, P., Leonard, G. D., Nguyen, D., Guo, X., Szabo, E. M., Hopkins, J. L., Leguizamo, J., Harold, N., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2439 · Cited by 6
Song, M., Guo, H., Chen, H., & Hu, H. (2016) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12203 · Cited by 6
Natural and Acquired Resistance to Cancer Therapies
Sikic, B. I. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00047-0 · Cited by 8
Avolio, M., Leto, S. M., Sassi, F. P., Lupo, B., Grassi, E., Catalano, I., Zanella, E. R., Vurchio, V., Cottino, F., Tsantoulis, P. K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0556 · Cited by 9
Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29)
Zeynali-Moghaddam, S., Kheradmand, F., Aziz, S. G., & Abroon, S. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103850 · Cited by 5
Adjuvant Treatment in Colorectal Cancer
Ivanov, K., Kolev, N. Y., Shterev, I., Tonev, A. Y., Ignatov, V., Bojkov, V., & Kirilov, T. (2014) · InTech eBooks · doi:10.5772/56914 · Cited by 5
Predictive “omic” biomarkers of drug response: Colorectal cancer as a model
Mini, E., Landini, I., Paolo, A. D., Ravegnini, G., Saponara, S., Frosini, M., Lapucci, A., & Nobili, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00002-0 · Cited by 5
Pradeepa, Suresh, V., Senapati, S., & Chakraborty, S. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00690-9 · Cited by 5
Sato, K., Kitajima, Y., Kohya, N., Koga, Y., Ohtaka, K., & Miyazaki, K. (2007) · PubMed · Cited by 5
Molecular Mechanisms of Breast Cancer Drug Resistance and CRISPR/Cas9 Strategies to Overcome
Hussen, B. M., Ismael, B. S., Abdulla, S. S., Jamal, N. H., Mustafa, S. A., Najmalddin, Z. B., & Rasul, M. F. (2024) · BioMed Target Journal · doi:10.59786/bmtj.221 · Cited by 5
Metadata
- Authors
- Xu, Y., & Villalona-Calero, M. A.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Villalona-Calero, M.A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 13
- Issue
- 12
- Pages
- 1841-1851
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2112055293
- Cited by
- 413
- References
- 124
- Citations by year
- 2026: 25 · 2025: 18 · 2024: 25 · 2023: 40 · 2022: 30 · 2021: 23 · 2020: 24 · 2019: 17 · 2018: 16 · 2017: 22 · 2016: 15 · 2015: 24 · 2014: 13 · 2013: 11 · 2012: 10
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 6246 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, topoisomerase I, drug resistance, drug efflux, proteasomal degradation, DNA repair, NF-κB, apoptosis, anticancer drug metabolism, combination therapy
- MeSH terms
- Irinotecan, Animals, Camptothecin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Neoplasms, Sensitivity and Specificity, NF-kappa B, Apoptosis, Risk Assessment, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.